Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;81(6):e28-e30.
doi: 10.1016/j.jinf.2020.07.029. Epub 2020 Jul 31.

Characterising differential antibody response is integral to future SARS-CoV-2 serostudies

Scott John Charles Pallett  1 , Rachael Jones  2 , Mitchell Anthony Pallett  2 , Michael Rayment  2 , Nabeela Mughal  2 , Gary William Davies  2 , Luke Stephen Prockter Moore  2
Affiliations
Comment

Characterising differential antibody response is integral to future SARS-CoV-2 serostudies

Scott John Charles Pallett et al. J Infect. 2020 Dec.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig. 1
Information available on serological targets from commercially available lateral flow assays (LFA) and laboratory immunoassays (enzyme-linked immunosorbent assays or chemiluminescence immunoassays) for SARS-CoV-2. Assays identified via an online repository and cross referenced with regulatory and advisory body online lists for current commercially available serology-based tests for SARS-CoV-2 (US Food and Drugs Administration, Australian Therapeutic Goods Administration, Health Information and Quality Authority, World Health Organisation). Information was taken directly from product listings and inserts on manufacturer and/or distributor sites and cross-referenced against documentation available for product regulatory approval. Circle size is relative to number of assays found within that category and recorded as: (i) no identifiable reference to any target found (ii) non-specific reference to assay targets including SARS-CoV-2 antigens, recombinant proteins, SARS-CoV-2 peptides, SARS-CoV-2 antibodies (iii) nucleocapsid protein (iv) spike protein, including specifically the S1 protein, N-terminus and RBD separately specified and (v) combination targets including to both nucleocapsid and spike proteins.
See this image and copyright information in PMC

Comment on

References

    1. Tre-Hardy M., Blairon L., Wilmet A., Beukinga I., Malonne H., Dogne J.M., et al. The role of serology for COVID-19 control: population, kinetics and test performance do matter. J Infect. 2020 doi: 10.1016/j.jinf.2020.05.019. [Epub ahead of print] - DOI - PMC - PubMed
    1. Jiang S., Hilyer C., Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355–359. doi: 10.1016/j.it.2020.03.007. - DOI - PMC - PubMed
    1. Thevarajan I., Nguyen T.H.O., Koutsakos M., Druce J., Caly L. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455. - PMC - PubMed
    1. Tay M.Z., Poh C.K., Renia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;28:1–12. doi: 10.1038/s41577-020-0311-8. - DOI - PMC - PubMed
    1. Quinlan B.D., Mou H., Zhang L., Guo Y., He W. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. 2020. bioRxiv preprint10.1101/2020.04.10.036418. Accessed May 21, 2020.

Substances